COMPASS Pathways Plc - American Depository Shares (CMPS)

COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the review process for psychedelic‑based treatments.

Compass Pathways may be the first to benefit from an accelerated approval process.

Trump is easing approval for psychedelic treatments for mental disorders.

Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and Reclaiming Your Life.

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more radical, rapid-acting interventions. At the forefront of this neuro-psychiatric revolution stands GH Research PLC (Nasdaq: GHRS), a Dublin-based biopharmaceutical firm that has just crossed a critical threshold [...]

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter.

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.